trending Market Intelligence /marketintelligence/en/news-insights/trending/B_yRydRWQ6gP_xBAjDn6VA2 content esgSubNav
In This List

TransEnterix's Senhance Ultrasonic system for robotic surgeries gets FDA nod

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


TransEnterix's Senhance Ultrasonic system for robotic surgeries gets FDA nod

TransEnterix Inc.'s Senhance Ultrasonic system, part of the company's robotic surgery platform for use in minimally invasive surgeries, has been approved by the U.S. Food and Drug Administration.

The Morrisville, N.C.-based medical device maker said in a Jan. 15 press release that the addition of ultrasonic technology was a significant expansion to its Senhance system, which is the first abdominal robotic surgery platform to receive FDA clearance since 2000.

The Senhance system itself is already cleared in the U.S. for laparoscopic colorectal, gynecological, inguinal hernia and gallbladder removal surgery. With the FDA nod, the Senhance Ultrasonic system is now available in the U.S., as well as all countries that accept a CE Mark designation for the product.

TransEnterix said advanced energy devices, including ultrasonic devices, are critical tools for surgeons in minimally invasive surgery as they deliver controlled energy to effectively ligate and divide tissue, while minimizing thermal injury to surrounding areas.